Related Experiment Video

Updated: May 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statin-mediated low-density lipoprotein lowering in chronic congestive heart failure

Constantine E Kosmas1, Hassan Alkhawam, Mohammed El-Hunjul

  • 1Zena and Michael A. Wiener Cardiovascular Institute (CEK), Mount Sinai School of Medicine, New York, New York; Faculty of Medicine (HA, ME-H), Cairo University, Cairo, Egypt; St. Francis Hospital-The Heart Center (GW, TJV), Division of Cardiology, Center of Advanced Cardiac Therapeutics, Roslyn, New York; Department of Internal Medicine (MRK), Mount Sinai School of Medicine, New York, New York; and Cardiovascular Consultants of Long Island (KMG), PC, New Hyde Park, New York.

The American Journal of the Medical Sciences
|November 17, 2012
PubMed

Insights

Statins do not improve survival in congestive heart failure (CHF). While beneficial for ischemic heart failure, their role in non-ischemic CHF remains uncertain, with potential risks from excessive low-density lipoprotein (LDL) lowering.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic congestive heart failure (CHF) management involves understanding lipid-lowering therapies.
  • Statins are widely used for cardiovascular risk reduction, but their efficacy in CHF is debated.

Purpose of the Study:

  • To review the current evidence and theories regarding statin use in patients with chronic congestive heart failure (CHF).
  • To evaluate the impact of low-density lipoprotein (LDL) lowering on outcomes in different CHF populations.

Main Methods:

  • Review of existing clinical trials, including large randomized controlled trials like CORONA and GISSI-HF.
  • Discussion of proposed mechanisms for adverse statin effects in CHF, such as endotoxin levels and coenzyme Q10 reduction.

Main Results:

  • Statins do not reduce mortality in patients with non-ischemic heart failure.
  • Statins lower LDL cholesterol and may offer benefits in ischemic heart failure.
  • Concerns exist that excessive LDL reduction by statins might worsen CHF outcomes.

Conclusions:

  • The role of statins in CHF remains controversial and requires further investigation.
  • More clinical trials are necessary to definitively determine the effects of statins on CHF patients.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...